CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 1.71 and has seen 0.52 million shares traded in the recent trading session. The company, currently valued at $3.36B, closed the recent trade at $39.04 per share which meant it gained $1.22 on the day or 3.22% during that session. The CRSP stock price is -73.87% off its 52-week high price of $67.88 and 23.05% above the 52-week low of $30.04. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.71 million shares traded. The 3-month trading volume is 2.31 million shares.
The consensus among analysts is that CRISPR Therapeutics AG (CRSP) is Buy stock at the moment, with a recommendation rating of 1.97. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.26.
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
Sporting 3.22% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CRSP stock price touched $39.04 or saw a rise of 2.13%. Year-to-date, CRISPR Therapeutics AG shares have moved -0.82%, while the 5-day performance has seen it change 0.58%. Over the past 30 days, the shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have changed -5.30%. Short interest in the company has seen 20.51 million shares shorted with days to cover at 11.75.
Wall Street analysts have a consensus price target for the stock at $67, which means that the shares’ value could jump 41.73% from the levels at last check today.. The projected low price target is $65.0 while the price target rests at a high of $95.0. In that case, then, we find that the latest price level in today’s session is -143.34% off the targeted high while a plunge would see the stock gain -66.5% from the levels at last check today..
CRISPR Therapeutics AG (CRSP) estimates and forecasts
The company’s shares have lost -19.16% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 58.92%.
15 analysts offering their estimates for the company have set an average revenue estimate of 5.96M for the current quarter. 15 have an estimated revenue figure of 8.65M for the next ending quarter. Year-ago sales stood 504k and 517k respectively for this quarter and the next, and analysts expect sales will grow by 1,083.48% for the current quarter and 58.92% for the next.
Earnings growth for 2025 is a modest -11.69% while over the next 5 years, the company’s earnings are expected to increase by 13.89%.
CRSP Dividends
CRISPR Therapeutics AG is expected to release its next earnings report on 2025-Feb-10 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Insiders own 1.65% of the company shares, while shares held by institutions stand at 77.30% with a share float percentage of 78.60%. Investors are also buoyed by the number of investors in a company, with CRISPR Therapeutics AG having a total of 542.0 institutions that hold shares in the company. The top two institutional holders are CAPITAL INTERNATIONAL INVESTORS with over 7.87 million shares worth more than $424.8 million. As of 2024-06-30, CAPITAL INTERNATIONAL INVESTORS held 9.2619% of shares outstanding.
The other major institutional holder is ARK INVESTMENT MANAGEMENT LLC, with the holding of over 7.78 million shares as of 2024-06-30. The firm’s total holdings are worth over $420.12 million and represent 9.1597% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Trust-ARK Innovation ETF and NEW PERSPECTIVE FUND . As of Mar 31, 2025 , the former fund manager holds about 8.31% shares in the company for having 7.18 shares of worth $279.55 million while later fund manager owns 2.55 shares of worth $99.4 million as of Mar 31, 2025 , which makes it owner of about 2.96% of company’s outstanding stock.
